292 related articles for article (PubMed ID: 12733850)
1. The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms.
J Toxicol Clin Toxicol; 2003; 41(2):131-5. PubMed ID: 12733850
[TBL] [Abstract][Full Text] [Related]
2. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
[TBL] [Abstract][Full Text] [Related]
3. Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy.
U.S. Xyrem Multicenter Study Group
Sleep Med; 2004 Mar; 5(2):119-23. PubMed ID: 15033130
[TBL] [Abstract][Full Text] [Related]
4. Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome.
Busardò FP; Kyriakou C; Napoletano S; Marinelli E; Zaami S
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4654-63. PubMed ID: 26698265
[TBL] [Abstract][Full Text] [Related]
5. Psychosis in the context of sodium oxybate therapy.
Langford J; Gross WL
J Clin Sleep Med; 2011 Dec; 7(6):665-6. PubMed ID: 22171207
[TBL] [Abstract][Full Text] [Related]
6. GHB levels in breast milk of women with narcolepsy with cataplexy treated with sodium oxybate.
Barker EC; Puchowicz M; Letterio J; Higgins K; Sharkey KM
Sleep Med; 2017 Aug; 36():172-177. PubMed ID: 28668666
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.
Bogan RK; Thorpy MJ; Dauvilliers Y; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Tang L; Skobieranda F; Šonka K
Sleep; 2021 Mar; 44(3):. PubMed ID: 33184650
[TBL] [Abstract][Full Text] [Related]
8. [Integrated treatment of the symptoms of narcolepsy-cataplexy syndrome with sodium oxybate].
Poza-Aldea JJ
Rev Neurol; 2009 Jan 1-15; 48(1):27-31. PubMed ID: 19145563
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
Bogan RK; Foldvary-Schaefer N; Skowronski R; Chen A; Thorpy MJ
CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322
[TBL] [Abstract][Full Text] [Related]
10. Sodium oxybate: efficacy, safety and tolerability in the treatment of narcolepsy with or without cataplexy.
Owen RT
Drugs Today (Barc); 2008 Mar; 44(3):197-204. PubMed ID: 18536781
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy.
Sleep; 2002 Feb; 25(1):42-9. PubMed ID: 11833860
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.
Xyrem International Study Group
J Clin Sleep Med; 2005 Oct; 1(4):391-7. PubMed ID: 17564408
[TBL] [Abstract][Full Text] [Related]
13. Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.
Dauvilliers Y; Šonka K; Bogan RK; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Chen A; Black J; Skobieranda F; Thorpy MJ
CNS Drugs; 2022 Jun; 36(6):633-647. PubMed ID: 35635687
[TBL] [Abstract][Full Text] [Related]
14. Comment on "The abrupt cessation of therapeutically administered sodium oxybate (GHB) may cause withdrawal symptoms".
Zvosec DL; Smith SW
J Toxicol Clin Toxicol; 2004; 42(1):121-3; author reply 125-7. PubMed ID: 15083950
[No Abstract] [Full Text] [Related]
15. Sodium oxybate: new drug. Fewer attacks of cataplexy in some patients.
Prescrire Int; 2007 Jun; 16(89):98-101. PubMed ID: 17582923
[TBL] [Abstract][Full Text] [Related]
16. Time to response with sodium oxybate for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.
Bogan RK; Roth T; Schwartz J; Miloslavsky M
J Clin Sleep Med; 2015 Apr; 11(4):427-32. PubMed ID: 25580605
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures.
Scrima L; Hartman PG; Johnson FH; Hiller FC
Biol Psychiatry; 1989 Aug; 26(4):331-43. PubMed ID: 2669980
[TBL] [Abstract][Full Text] [Related]
18. Sodium oxybate and sleep apnea: a clinical case.
Hartley S; Quera-Salva MA; Machou M
J Clin Sleep Med; 2011 Dec; 7(6):667-8. PubMed ID: 22171208
[TBL] [Abstract][Full Text] [Related]
19. Sodium oxybate for cataplexy.
Lemon MD; Strain JD; Farver DK
Ann Pharmacother; 2006 Mar; 40(3):433-40; quiz 581-2. PubMed ID: 16507620
[TBL] [Abstract][Full Text] [Related]
20. Gamma-hydroxybutyrate (GHB) for narcolepsy in adults: an updated systematic review and meta-analysis.
Xu XM; Wei YD; Liu Y; Li ZX
Sleep Med; 2019 Dec; 64():62-70. PubMed ID: 31671326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
